By |

Profile

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Contact Information

Website: www.curis.com
Email: info@curis.com
Main Phone: +1 617 503-6500
Address: 4 Maguire Road
State: MA
City / Town: Lexington
Country: USA
Postal Code: 02421

Issuer Information

Exchange: NSD
CEO: James E. Dentzer
Employees: 31
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)


Gathering Data... Please wait

Profile

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Contact Information

Website: www.curis.com
Email: info@curis.com
Main Phone: +1 617 503-6500
Address: 4 Maguire Road
State: MA
City / Town: Lexington
Country: USA
Postal Code: 02421

Issuer Information

Exchange: NSD
CEO: James E. Dentzer
Employees: 31
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
$ 2.12 $ 0.05 (2.42%)
Last Price 2.12 Change $ 0.05 Change % 2.42 Tick N/A
Bid 2.10 Bid Size 100.00 Ask 2.88 Ask Size 200.00
Open 2.03 High 2.15 Low 2.01 Prev Close 2.07
Last Trade Volume 94,969 52 Wk Hi 2.90 52 Wk Low 0.60
Market Cap 70.4 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 33,202,871.00 EPS (TTM) -0.92 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 10
Number of Buys 0 10
Number of Sells 0 0
Net Activity 0 1546250
Last 10 Buys Shares
Marc Rubin 1,000
Ali Fattaey 1,000
Ali Fattaey 1,000
Ali Fattaey 1,000
Kenneth J. Pienta 1,000
Kenneth J. Pienta 1,000
James R. Mcnab 1,000
Daniel R. Passeri 1,000
Kenneth I. Kaitin 1,000
Marc Rubin 1,000
Last 10 Sell Shares
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
James R. Mcnab 1,000
Martyn D. Greenacre 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 35 35 7 35
Low Target Price Estimate 15 15 3 15
Mean Target Price Estimate 22.67 22.5 4.5 22.67
Standard Deviation 10.79 10.9 2.18 10.79
Date of Most Recent Estimate 05/31/18 05/07/18 05/07/18 05/31/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1